CANX

Across TCGA pan-cancer cohorts, CANX mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CANX’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CANX mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CANX is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, CCRCC, and LUAD are the cancer types where CANX tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CANX mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.480	<.001	11	view →
CCRCC	Male	II,III,IV	+0.733	<.001	10	view →
LUAD	Female	III,IV	+0.818	<.001	9	view →
COAD	Female	II,III,IV	+0.320	<.001	9	view →
LSCC	Male	III,IV	+0.433	<.001	8	view →
PDAC	All	All	−0.557	<.001	6	view →
OV	All	All	+0.421	.022	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CANX–HNSC

Open the HNSC breakdown →